1. Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature
   Deborah van de Wal et al, 2022, Cancers CrossRef
2. The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review
   Vahe Khachatryan et al, 2022, Cureus CrossRef
3. A Potential Association of Zinc Deficiency and Tyrosine Kinase Inhibitor-Induced Hand-Foot Skin Reaction
   Chun-Nan Yeh et al, 2023, Biological Trace Element Research CrossRef
4. Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors
   Ryugo Teranishi et al, 2022, International Journal of Clinical Oncology CrossRef
5. Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry study
   Hui-Jen Tsai et al, 2024, BMC Cancer CrossRef
6. Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies
   Lei Wang et al, 2020, Frontiers in Oncology CrossRef
7. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience
   Li-Ching Lin et al, 2022, Frontiers in Oncology CrossRef